Your session is about to expire
← Back to Search
Antiplatelet Agent
Aspirin 81 mg for Heart Attack
Phase 3
Waitlist Available
Led By Jain Nishank, MD
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Males and females, aged 18-91 years
Ability to understand and sign informed consent after the nature of the study has been fully explained
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Study Summary
This trial is testing whether ticagrelor is better than clopidogrel at preventing heart problems in people with chronic kidney disease.
Eligible Conditions
- Heart Attack
- Ischemic Stroke
- Chronic Kidney Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
ADP Induced Platelet Aggregation
Secondary outcome measures
Platelet Surface P-selectin Expression
Side effects data
From 2011 Phase 2 & 3 trial • 93 Patients • NCT015869756%
Nose bleeds
3%
GI bleeding
3%
Clinical Stroke
100%
80%
60%
40%
20%
0%
Study treatment Arm
Aspirin 81 mg
Aspirin >300 mg
Clopidogrel 75 mg
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: CKD-TicagrelorExperimental Treatment2 Interventions
Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
Group II: Control-ticagrelorActive Control2 Interventions
Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
Group III: CKD-ClopidogrelActive Control2 Interventions
Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ticagrelor
FDA approved
Acetylsalicylic acid
FDA approved
Find a Location
Who is running the clinical trial?
University of ArkansasLead Sponsor
483 Previous Clinical Trials
148,451 Total Patients Enrolled
American Society of NephrologyOTHER
4 Previous Clinical Trials
432 Total Patients Enrolled
Jain Nishank, MDPrincipal InvestigatorUniversity of Arkansas for Medical
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger